Determination of glycated hemoglobin in clinically silent hemoglobin variants

被引:18
作者
Schnedl, WJ
Lahousen, T
Lang, T
Lipp, RW
Yonehara, S
Fukunaga, S
Imai, T
Little, RR
机构
[1] Graz Univ, Sch Med, Dept Internal Med, A-8036 Graz, Austria
[2] Graz Univ, Sch Med, Dept Psychiat, A-8036 Graz, Austria
[3] Arkray Inc, Lab Prod Div, Kyoto, Japan
[4] Univ Missouri, Sch Med, Dept Pathol & Child Hlth, Columbia, MO 65211 USA
关键词
glycated hemoglobin; hemoglobin variants; enzymatic assay; boronate affinity HPLC; immunoassay; ion-exchange HPLC;
D O I
10.1002/dmrr.483
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Evaluation of glycated hemoglobin determination methods in patients with clinically silent hemoglobin variants. Methods HbA(1c) results were determined with various methods, including a new enzymatic assay, a boronate affinity HPLC, immunoassays and ion-exchange HPLC in patients with the clinically silent hemoglobin variants Hb Graz, Hb Sherwood Forest, Hb D and Hb O Padova. Results The effect of hemoglobin variants on glycated hemoglobin determination was method-dependent. The enzymatic and boronate affinity HPLC method did not interfere with any of the variants evaluated. In contrast, Hb Graz interfered with all immunoassay and ion-exchange HPLC methods evaluated. The Tosoh ion-exchange HPLC method HLC-723 did not detect the late migrating Hb O Padova in the chromatogram, but this hemoglobin variant still interfered causing artificially low HbA(1c) results. Conclusions Our study underscores the need for clinical laboratories and physicians to be aware of the limitations of their HbA(1c) assay methods as well as the importance of visual inspection of ion-exchange chromatograms to detect abnormalities caused by the hemoglobin variants. Samples with clinically silent Hb variants should be analyzed by a second method with a different assay principle, preferably a boronate affinity HPLC or an enzymatic assay. Copyright (C) 2004 John Wiley Sons, Ltd.
引用
收藏
页码:460 / 465
页数:6
相关论文
共 15 条
[1]   DETERMINATION OF GLYCOSYLATED HEMOGLOBINS (HB-AI) WITH A NEW MICROCOLUMN PROCEDURE - SUITABILITY OF TECHNIQUE FOR ASSESSING CLINICAL MANAGEMENT OF DIABETES-MELLITUS [J].
ABRAHAM, EC ;
HUFF, TA ;
COPE, ND ;
WILSON, JB ;
BRANSOME, ED ;
HUISMAN, THJ .
DIABETES, 1978, 27 (09) :931-937
[2]  
*AM DIAB ASS, 2003, DIABETES CARE, V26, pS106
[3]  
Bry L, 2001, CLIN CHEM, V47, P153
[4]   Discordance between HbA1c and fructosamine -: Evidence for a glycosylation gap and its relation to diabetic nephropathy [J].
Cohen, RM ;
Holmes, YR ;
Chenier, TC ;
Joiner, CH .
DIABETES CARE, 2003, 26 (01) :163-167
[5]  
Gibb I, 1999, CLIN CHEM, V45, P1833
[6]  
JOHN WG, 2002, CLIN CHEM LAB MED, V40, pS106
[7]   Silent haemoglobin variants and determination of HbA1c with the HPLC Bio-Rad Variant II [J].
Lahousen, T ;
Roller, RE ;
Lipp, RW ;
Schnedl, WJ .
JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (09) :699-703
[8]   Recent progress in glycohemoglobin (HbA1c) testing [J].
Little, RR .
DIABETES CARE, 2000, 23 (03) :265-266
[9]  
Little RR, 2001, CLIN CHEM, V47, P1985
[10]  
Roberts WL, 2002, CLIN CHEM, V48, P383